Skip to main content

Organoids as clinically relevant models to tailor precision medicine in cancer treatment

New Content Item

Journal of Experimental & Clinical Cancer Research is welcoming papers on: 

Organoids as clinically relevant models to tailor precision medicine in cancer treatment

Guest Editors: Sabrina Arena1, Giovanni Blandino2, Alice Castelli3, Cyril Corbet4

1- Associate Professor, University of Turin and Group Leader, Candiolo Cancer Institute, Turin, Italy
2- Head of Translational Oncology Research Unit
, Regina Elena National Cancer Institute, Rome, Italy
3- Managing Editor, Journal of  Experimental & Clinical Cancer Research, Regina Elena National Cancer Institute, Rome, Italy
4- Institut de Recherche Expérimentale et Clinique, Pole of Pharmacology and Therapeutics, University of Louvain, Brussels, Belgium

Submission window: January 1st 2023 – December 31st 2023. Submit your research here

The expanding field of precision medicine in oncology requires an accurate profiling of tumors to identify effectively targetable alterations and to translate preclinical discoveries into clinical benefit for cancer patients. This approach has led to the replacement of the one-size-fits-all therapies by more effective and individualized treatments. This goal has been recently achieved not only thanks to the use of powerful sequencing technologies for tumor molecular profiling, but also thanks to the development of novel preclinical models more closely resembling patients ‘tumors. Organoids are self-assembling, organ-like, three-dimensional cellular structures that thoroughly retain in vitro key characteristics of the respective tissue of origin. Organoids can be obtained both from normal or tumor tissue, allowing the wide and potentially infinite expansion of material for research and preclinical studies that have already shown a significant impact in the clinical arena. Cancer organoid platforms have provided valuable tools to test next-generation drugs and novel therapeutic strategies to foster personalized medical decisions and to potentially improve treatment outcomes starting from real “patient avatars”.

With this special collection we aim at presenting the latest highlights and state-of-art applications involving the use of organoids to improve therapeutic strategies and to tailor a more personalized approach in cancer treatment.

Keywords: Organoids, Oncology, Cancer, Chemotherapy, Targeted therapy, precision medicine, preclinical models.

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system. Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.

  1. Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. Large-scale metabolomic data have associated metabolic alterations with the pathogenesis and progression of renal carcinoma a...

    Authors: Christofer Rupert, Carmela Dell’ Aversana, Laura Mosca, Vittorino Montanaro, Davide Arcaniolo, Marco De Sio, Antonio Bilancio, Lucia Altucci, Wulf Palinski, Roberto Pili and Filomena de Nigris
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:134
  2. High grade serous ovarian cancer (HGSOC) is highly lethal, partly due to chemotherapy resistance and limited availability of targeted approaches. Cyclin dependent kinases 12 and 13 (CDK12/13) are promising the...

    Authors: Eleonora Cesari, Alessandra Ciucci, Marco Pieraccioli, Cinzia Caggiano, Camilla Nero, Davide Bonvissuto, Francesca Sillano, Marianna Buttarelli, Alessia Piermattei, Matteo Loverro, Floriana Camarda, Viviana Greco, Maria De Bonis, Angelo Minucci, Daniela Gallo, Andrea Urbani…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:126
  3. Patients with colorectal metastatic disease have a poor prognosis, limited therapeutic options, and frequent development of resistance. Strategies based on tumor-derived organoids are a powerful tool to assess...

    Authors: Lars Henrik Jensen, Silvia Regina Rogatto, Jan Lindebjerg, Birgitte Havelund, Cecilie Abildgaard, Luisa Matos do Canto, Chris Vagn-Hansen, Claus Dam, Søren Rafaelsen and Torben Frøstrup Hansen
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:115
  4. Immunotherapy as a rapidly developing therapeutic approach has revolutionized cancer treatment and revitalized the field of tumor immunology research. 3D in vitro models are emerging as powerful tools consider...

    Authors: Peiyuan Mu, Shujuan Zhou, Tao Lv, Fan Xia, Lijun Shen, Juefeng Wan, Yaqi Wang, Hui Zhang, Sanjun Cai, Junjie Peng, Guoqiang Hua and Zhen Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:81
  5. We propose a new approach for designing personalized treatment for colorectal cancer (CRC) patients, by combining ex vivo organoid efficacy testing with mathematical modeling of the results.

    Authors: George M. Ramzy, Maxim Norkin, Thibaud Koessler, Lionel Voirol, Mathieu Tihy, Dina Hany, Thomas McKee, Frédéric Ris, Nicolas Buchs, Mylène Docquier, Christian Toso, Laura Rubbia-Brandt, Gaetan Bakalli, Stéphane Guerrier, Joerg Huelsken and Patrycja Nowak-Sliwinska
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:79